Does Rallies show 13F holders for KYMR?

Yes. Rallies tracks hedge fund and 13F ownership data for KYMR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KYMR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KYMR. It does not provide personalized investment advice.

KYMR (Kymera Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Kymera Therapeutics, Inc. Common Stock (KYMR) is a publicly traded Healthcare sector company. As of May 21, 2026, KYMR trades at $80.28 with a market cap of $6.55B and a P/E ratio of -21.86. KYMR moved +3.33% today. Year to date, KYMR is +11.38%; over the trailing twelve months it is +156.52%. Its 52-week range spans $19.45 to $103.00. Analyst consensus is strong buy with an average price target of $119.07. Rallies surfaces KYMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KYMR stock?

Hedge funds tracked by Rallies that own KYMR include Redmile Group and Soros Fund. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kymera Therapeutics, Inc. Common Stock.

KYMR Key Metrics

Key financial metrics for KYMR
Metric	Value
Price	$80.28
Market Cap	$6.55B
P/E Ratio	-21.86
EPS	$-3.69
Dividend Yield	0.00%
52-Week High	$103.00
52-Week Low	$19.45
Volume	321
Avg Volume	0
Revenue (TTM)	$39.21M
Net Income	$-311.35M
Gross Margin	0.00%

Top Hedge Funds Holding KYMR

Redmile Group holds 803.29K shares of KYMR, changed -18.32% as of Jun 30, 2025.
Soros Fund holds 120.37K shares of KYMR, changed +0.00% as of Dec 31, 2024.

Latest KYMR News

Kymera climbs as Fast Track KT-621 momentum and May conference catalysts fuel bid — May 6, 2026
Kymera’s KT-579 Matches JAK Inhibitors, Completely Blocks TNFα and IL-6 in IBD Model — May 5, 2026
Kymera climbs as Gilead milestone, big cash runway, May KT-621 catalysts refocus buyers — May 4, 2026
Kymera slides after Q1 results as investors weigh cash burn and R&D ramp — Apr 30, 2026
Kymera Nets $45M Milestone, $1.55B Cash Runway and KT-621 Phase 2b Progress — Apr 30, 2026

Recent KYMR Insider Trades

Ridloff Elena sold 3.00K (~$261.00K) on May 11, 2026.
Mainolfi Nello sold 17.00K (~$1.37M) on Apr 29, 2026.
Mainolfi Nello sold 12.06K (~$985.22K) on Apr 29, 2026.

KYMR Analyst Consensus

16 analysts cover KYMR: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $119.07.

Common questions about KYMR

Who owns KYMR stock?: Hedge funds tracked by Rallies that own KYMR include Redmile Group and Soros Fund. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kymera Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for KYMR?: Yes. Rallies tracks hedge fund and 13F ownership data for KYMR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KYMR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KYMR. It does not provide personalized investment advice.